Alliances
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 17, 2020.
The two companies will evaluate the combination of Sinovac’s chemically inactivated coronavirus vaccine candidate, with Dynavax’s advanced adjuvant, CpG 1018.
The two companies will evaluate a smartphone-based self-testing solution for COVID-19, using Luminostics’ innovative technology and Sanofi’s clinical research abilities.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 16, 2020.
“It is always great to work with the forward-thinking leaders in cell and gene therapy, like Achilles, who are focused on innovating across the board, not just clinically and scientifically but also technologically. We see huge potential for the future of this partnership,” said Farlan Veraitch, Co-Founder and CSO, Ori Biotech.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 15, 2020.
Under the terms of the deal, Novartis is paying TScan an upfront technology access fee and research funding totaling $30 million.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 14, 2020.
“Blackstone is uniquely positioned to provide customized, one-stop-shop financing solutions at scale while establishing development collaborations with the world’s leading biotech companies,” said Nicholas Galakatos, global head of Blackstone Life Sciences.
The two companies are eying the second half of this year to begin clinical trials on their combined project and, if the vaccine meets expectations, the companies said it could be available for use in the second half of 2021.
PRESS RELEASES